How will the JAK inhibitor class-wide black box warning affect perceptions of Opzelura for atopic dermatitis?

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

0

0

0 Comments

0

0

• Dermatology
• P&T Perspectives
• P&T Sessions
• Pharma